Anaptys surges as arthritis therapy succeeds in mid-stage trial

Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune disorder rheumatoid arthritis.

Citing 12-week data from its global